Sudeep Pharma IPO: The good and the bad

Summary: Sudeep Pharma, a manufacturer of pharma and specialty nutrition ingredients, is set to go public on November 21, 2025. We analyse the company’s strengths, drawbacks and past track record to help you better understand whether its IPO is worth subscribing to. Sudeep Pharma, a manufacturer of pharma excipients and specialty nutrition ingredients, will open its IPO (initial public offering) on November 21, 2025 and close on November 25, 2025. Of the total issue size of Rs 895 crore, Rs 95 crore comprises a fresh issue, while Rs 800 crore will be an offer for sale (OFS). Below is a breakdown of Sudeep Pharma’s business, financials, strengths, risks and valuation to help you make an informed investment decision. What the company does Sudeep Pharma is a technology-driven manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food and nutrition industries. The company uses in-house technologies such as encapsulation, spray drying and liposomal preparation to strengthen product innovation. The company has a meaningful presence across major global markets, including the US, Europe and Asia-Pacific. Sudeep Pharma is among the largest producers of food-grade iron phosphate and a leading exporter of mineral ingredients from India. The company is also an early mover in liposomal ingredient technology. Track record and valuation When it comes to past financials, Sudeep Pharma appears to be on an impressive footing. Though the company’s revenue grew at a modest 8.2 per cent between FY23 and FY25, its PAT (profit after tax) and EBIT (earnings per share) both posted a strong growth of 49 per cent. At the upper end of the price band (Rs 593), Sudeep Pharma’s stock is expected to be valued at 48 times its FY25 earnings and around 8.7 times its book value. There are no listed peers for comparison. Sudeep Pharma IPO analysis Total IPO size (Rs cr) 895 Offer for sale (Rs cr) 800 Fresh issue (Rs cr) 95 Price band (Rs) 563-593 Subscription dates November 21-25, 2025 Purpose of issue Capex towards procurement of new machinery for the company's production line in Nandesari Post-IPO M-cap (Rs cr) 6,698 Net worth (Rs cr) 776 Promoter holding (%) 76.2 Price/earnings ratio (P/E) 48.3 Price/book ratio (P/B) 8.7 Financial history Key financials 2Y CAGR (%)